The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA
Portfolio Pulse from
The Gross Law Firm has initiated a class action lawsuit against Intellia Therapeutics, alleging that the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency. The lawsuit claims Intellia failed to disclose the declining relevance of viral-based editing methods. On January 9, 2025, Intellia announced a reorganization, halting NTLA-3001 research and reducing workforce by 27%, causing the stock price to drop from $12.02 to $10.20.
April 10, 2025 | 10:00 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia Therapeutics is facing a class action lawsuit alleging misleading statements about its NTLA-3001 program, which was discontinued as part of a major corporate reorganization.
The lawsuit and corporate restructuring directly impact Intellia's stock by highlighting potential misrepresentations, signaling strategic uncertainties, and demonstrating reduced research capabilities.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100